Luteal Phase Support using Oral Dydrogesterone-a
Prospective Treatment for Future Replacing
Micronized Vaginal Progesterone
Volume 1 - Issue 4
Kulvinder Kochar Kaur1*, Gautam Allahbadia2 and Mandeep Singh3
-
Author Information
Open or Close
- 1Scientific Director, Centre For Human Reproduction, Punjab, India
- 2Department of Obstetrics and Gynecology, Mumbai, India
- 3Department of Neurology, Swami Satyanand Hospital, Punjab, India
*Corresponding author:
Kulvinder Kochar Kaur, Scientific Director, Centre For Human Reproduction 721, G.T.B. Nagar,
Jalandhar-144001, Punjab, India
Received: September 03, 2018; Published: September 10, 2018
DOI: 10.32474/OAJRSD.2018.01.000119
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Although micronized vaginal progesterone is the accepted norm for use in luteal phase support (LPS) in controlled ovarian
stimulation (COS) that is used for in vitro fertilization (IVF) cycles, recently importance of oral Dydrogesterone has got the
importance in lieu of its oral availability, cheap, no cumbersome side effects and no definitive newer fetal side effects. After the
LOTUS 1 trial with a multicenter double placebo, double dummy design it has proved an equal efficacy if not superiority of oral D,
over micronized vaginal progesterone and it seems D might soon become the standard of care for LPS in conventional IVF cycles
besides its routine indication for recurrent abortions.
Keywords: LPS; COS; IVF; Dydrogesterone; Micronized vaginal progesterone
Abbreviations: LPS: Luteal Phase Support; COS: Controlled Ovarian Stimulation; IVF: In Vitro Fertilization; ET: Embryo Transfer
Abstract|
Dydrogesterone(D)-Pharmacology|
Advantages of an Oral preparation over other
Routes|
Problem of Vaginal administration for the Treating
Physician|
Safety of oral D|
Fetal Safety|
Cost Effectiveness of D|
Conclusions|
References|